Virtu Financial LLC Clovis Oncology, Inc. Transaction History

Virtu Financial LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$1.05 - $2.85 $56,119 - $152,323	53,447 New	53,447 $64,000
Q1 2022 May 17, 2022	SELL	$1.43 - $3.14 $91,700 - $201,355	-64,126 Closed	0 $0
Q4 2021 Feb 17, 2022	SELL	$2.7 - $4.76 $111,877 - $197,235	-41,436 Reduced 39.25%	64,126 $174,000
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $269,713 - $385,305	-66,432 Reduced 38.62%	105,562 $471,000
Q2 2021 Sep 17, 2021	BUY	$5.02 - $7.05 $863,409 - $1.21 Million	171,994 New	171,994 $998,000
Q4 2020 Feb 24, 2021	SELL	$4.13 - $6.41 $351,359 - $545,330	-85,075 Closed	0 $0
Q3 2020 Dec 11, 2020	BUY	$4.82 - $7.72 $410,061 - $656,779	85,075 New	85,075 $496,000
Q2 2020 Aug 07, 2020	SELL	$5.69 - $9.69 $139,814 - $238,102	-24,572 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$3.0 - $16.43 $73,716 - $403,717	24,572 New	24,572 $256,000
Q2 2019 Aug 13, 2019	SELL	$12.81 - $25.67 $111,049 - $222,533	-8,669 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$17.66 - $30.28 $153,094 - $262,497	8,669 New	8,669 $215,000
Q4 2017 Feb 09, 2018	SELL	$57.69 - $84.58 $473,577 - $694,317	-8,209 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$67.17 - $84.81 $551,398 - $696,205	8,209	8,209 $676,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.